|
18 Sep 2020 |
Agenus Presents Results from Two Large Cervical Cancer Trials at ESMO
|
|
18 Sep 2020 |
Expanding Their Existing Strategic Collaboration, GenScript ProBio Licensed Global Rights to Develop and Commercialize a SMAB Bispecific Antibody Molecule to REMD Biotherapeutics Inc.
|
|
18 Sep 2020 |
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer
|
|
18 Sep 2020 |
ADC Therapeutics Announces Presentation of Preliminary Findings from Phase 1b Clinical Trial of Camidanlumab Tesirine (Cami) in Advanced Solid Tumors at ESMO Virtual Congress 2020
|
|
18 Sep 2020 |
Celltrion receives Korean MFDS approval to initiate Phase II/III pivotal trial of an anti-COVID-19 monoclonal antibody treatment candidate, CT-P59
|
|
18 Sep 2020 |
Imfinzi demonstrated unprecedented survival in unresectable, Stage III non-small cell lung cancer with an estimated 50% of patients surviving four years
|
|
18 Sep 2020 |
Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO
|
|
18 Sep 2020 |
Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC at ESMO 2020
|
|
18 Sep 2020 |
ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks
|
|
18 Sep 2020 |
Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies
|
|
18 Sep 2020 |
Genentech’s Phase III EMPACTA Study Showed Actemra Reduced the Likelihood of Needing Mechanical Ventilation in Hospitalized Patients With COVID-19 Associated Pneumonia
|
|
17 Sep 2020 |
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trial of STI-1499 (COVI-GUARD) Neutralizing Antibody in COVID-19 Positive Patients
|
|
17 Sep 2020 |
Immune-Onc Therapeutics Announces First Patient Dosed in Phase I Trial Evaluating IO-202, a First-In-Class Antibody for the Treatment of Acute Myeloid Leukemia
|
|
17 Sep 2020 |
Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
|
|
16 Sep 2020 |
aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Doses First Subjects in Phase 1 Trial of ATYR1923 in Japan
|
|
16 Sep 2020 |
EpimAb Biotherapeutics Announces FDA Clearance of its IND Application for EMB-02, a Bispecific Dual Checkpoint Inhibitor
|
|
16 Sep 2020 |
Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors
|
|
16 Sep 2020 |
Cullinan Oncology, German Cancer Research Center (DKFZ) and the University of Tübingen Announce the Formation of Cullinan Florentine to Develop CLN-049, a Novel Bispecific Antibody for AML
|
|
16 Sep 2020 |
Novus Therapeutics Announces Acquisition of Anelixis Therapeutics
|
|
16 Sep 2020 |
Gilead’s Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome
|
|
14 Sep 2020 |
RECOVERY COVID-19 Phase 3 Trial to Evaluate Regeneron's REGN-COV2 Investigational Antibody Cocktail in the UK
|
|
14 Sep 2020 |
PharmAbcine Unveils Olinvacimab's Positive Results from Phase Ib Combination Studies at KSMO 2020
|
|
14 Sep 2020 |
Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal Cancer
|
|
14 Sep 2020 |
Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis
|
|
14 Sep 2020 |
HiFiBiO Therapeutics Announces a Global Strategic Partnership With ABL Bio for the Co-Development of a SARS-CoV-2 Neutralizing Antibody
|
